Almirall and IRB Barcelona team up to tackle skin disease
pharmaphorum
JANUARY 18, 2022
The use of monovalent degraders, which enable the targeted degradation of disease-relevant proteins, offers a new avenue to reach tissue that cannot be targeted with conventional therapeutic agents. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.
52 
Let's personalize your content